MARKET

PTLA

PTLA

Portola Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.25
-0.96
-3.29%
Closed 18:55 12/09 EST
OPEN
29.32
PREV CLOSE
29.21
HIGH
29.53
LOW
28.18
VOLUME
928.26K
TURNOVER
--
52 WEEK HIGH
37.95
52 WEEK LOW
14.81
MARKET CAP
2.20B
P/E (TTM)
-6.8102
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PTLA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PTLA News

  • Portola Pharma Highlights Presentation Of New Interim Data On Oral Cerdulatinib At ASH
  • Benzinga.12h ago
  • Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
  • PR Newswire.12h ago
  • Should You Buy Portola Pharmaceuticals Inc (PTLA)?
  • Insider Monkey.18h ago
  • Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
  • Benzinga.1d ago

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About PTLA

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
More

Webull offers Portola Pharmaceuticals Inc (PTLA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.